S&P 500   4,622.44 (+0.39%)
DOW   36,404.93 (+0.43%)
QQQ   395.52 (+0.85%)
AAPL   193.18 (-1.29%)
MSFT   371.30 (-0.78%)
META   325.28 (-2.24%)
GOOGL   133.29 (-1.26%)
AMZN   145.89 (-1.04%)
TSLA   239.74 (-1.68%)
NVDA   466.27 (-1.85%)
NIO   7.68 (+4.07%)
BABA   71.37 (-1.07%)
AMD   134.41 (+4.26%)
T   16.62 (-1.77%)
F   11.07 (+0.54%)
MU   77.79 (+3.78%)
CGC   0.73 (-8.34%)
GE   120.28 (-0.26%)
DIS   92.20 (-0.67%)
AMC   7.11 (+2.60%)
PFE   28.64 (-0.49%)
PYPL   59.04 (+0.17%)
XOM   99.62 (+0.07%)
S&P 500   4,622.44 (+0.39%)
DOW   36,404.93 (+0.43%)
QQQ   395.52 (+0.85%)
AAPL   193.18 (-1.29%)
MSFT   371.30 (-0.78%)
META   325.28 (-2.24%)
GOOGL   133.29 (-1.26%)
AMZN   145.89 (-1.04%)
TSLA   239.74 (-1.68%)
NVDA   466.27 (-1.85%)
NIO   7.68 (+4.07%)
BABA   71.37 (-1.07%)
AMD   134.41 (+4.26%)
T   16.62 (-1.77%)
F   11.07 (+0.54%)
MU   77.79 (+3.78%)
CGC   0.73 (-8.34%)
GE   120.28 (-0.26%)
DIS   92.20 (-0.67%)
AMC   7.11 (+2.60%)
PFE   28.64 (-0.49%)
PYPL   59.04 (+0.17%)
XOM   99.62 (+0.07%)
S&P 500   4,622.44 (+0.39%)
DOW   36,404.93 (+0.43%)
QQQ   395.52 (+0.85%)
AAPL   193.18 (-1.29%)
MSFT   371.30 (-0.78%)
META   325.28 (-2.24%)
GOOGL   133.29 (-1.26%)
AMZN   145.89 (-1.04%)
TSLA   239.74 (-1.68%)
NVDA   466.27 (-1.85%)
NIO   7.68 (+4.07%)
BABA   71.37 (-1.07%)
AMD   134.41 (+4.26%)
T   16.62 (-1.77%)
F   11.07 (+0.54%)
MU   77.79 (+3.78%)
CGC   0.73 (-8.34%)
GE   120.28 (-0.26%)
DIS   92.20 (-0.67%)
AMC   7.11 (+2.60%)
PFE   28.64 (-0.49%)
PYPL   59.04 (+0.17%)
XOM   99.62 (+0.07%)
S&P 500   4,622.44 (+0.39%)
DOW   36,404.93 (+0.43%)
QQQ   395.52 (+0.85%)
AAPL   193.18 (-1.29%)
MSFT   371.30 (-0.78%)
META   325.28 (-2.24%)
GOOGL   133.29 (-1.26%)
AMZN   145.89 (-1.04%)
TSLA   239.74 (-1.68%)
NVDA   466.27 (-1.85%)
NIO   7.68 (+4.07%)
BABA   71.37 (-1.07%)
AMD   134.41 (+4.26%)
T   16.62 (-1.77%)
F   11.07 (+0.54%)
MU   77.79 (+3.78%)
CGC   0.73 (-8.34%)
GE   120.28 (-0.26%)
DIS   92.20 (-0.67%)
AMC   7.11 (+2.60%)
PFE   28.64 (-0.49%)
PYPL   59.04 (+0.17%)
XOM   99.62 (+0.07%)

bioAffinity Technologies (BIAF) Stock Price, News & Analysis

$1.39
-0.02 (-1.42%)
(As of 05:19 PM ET)
Compare
Today's Range
$1.39
$1.49
50-Day Range
$1.15
$1.69
52-Week Range
$0.95
$3.99
Volume
15,000 shs
Average Volume
352,676 shs
Market Capitalization
$13.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

BIAF stock logo

About bioAffinity Technologies Stock (NASDAQ:BIAF)

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.

BIAF Stock Price History

BIAF Stock News Headlines

Countries Are Investing Heavily Into Securing Energy Independence
There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.
SA biotech hire to bolster national expansion
Countries Are Investing Heavily Into Securing Energy Independence
There's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.
Bioaffinity Technologies Inc Com
BIAF bioAffinity Technologies, Inc.
See More Headlines
Receive BIAF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for bioAffinity Technologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
12/11/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/29/2024

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BIAF
Fax
N/A
Employees
14
Year Founded
N/A

Profitability

Net Income
$-8,150,000.00
Net Margins
-2,244.15%
Pretax Margin
-2,240.12%

Debt

Sales & Book Value

Annual Sales
$321,489.00
Book Value
$1.32 per share

Miscellaneous

Free Float
5,293,000
Market Cap
$13.97 million
Optionable
Not Optionable
Beta
3.80
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Steven Girgenti (Age 77)
    Founder & Executive Chairman of the Board
    Comp: $93.33k
  • Ms. Maria Zannes J.D. (Age 67)
    Founder, President, CEO & Director
    Comp: $260.81k
  • Dr. Vivienne I. Rebel M.D. (Age 58)
    Ph.D., Executive VP and Chief Medical & Science Officer
    Comp: $238.39k
  • Mr. Michael Dougherty CPA (Age 45)
    M.B.A., VP & CFO
  • Mr. Xavier T. Reveles M.S. (Age 54)
    Chief Operating Officer
  • Mr. Timothy P. Zannes J.D. (Age 70)
    Executive VP, Secretary & General Counsel
  • Ms. Julie Anne Overton
    Director of Communications
  • Mr. Dallas J. Coleman
    National Director of Sales
  • Dr. William Bauta Ph.D.
    Senior Vice President of Therapeutics














BIAF Stock Analysis - Frequently Asked Questions

How have BIAF shares performed in 2023?

bioAffinity Technologies' stock was trading at $1.60 on January 1st, 2023. Since then, BIAF stock has decreased by 8.1% and is now trading at $1.47.
View the best growth stocks for 2023 here
.

When is bioAffinity Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 29th 2024.
View our BIAF earnings forecast
.

How were bioAffinity Technologies' earnings last quarter?

bioAffinity Technologies, Inc. (NASDAQ:BIAF) announced its quarterly earnings data on Tuesday, November, 14th. The company reported ($0.26) earnings per share (EPS) for the quarter. The firm had revenue of $0.30 million for the quarter. bioAffinity Technologies had a negative trailing twelve-month return on equity of 80.82% and a negative net margin of 2,244.15%.

When did bioAffinity Technologies IPO?

(BIAF) raised $8 million in an initial public offering on Thursday, September 1st 2022. The company issued 1,300,000 shares at a price of $6.00-$6.25 per share. WallachBeth Capital acted as the underwriter for the IPO and Craft Capital Management was co-manager.

How do I buy shares of bioAffinity Technologies?

Shares of BIAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:BIAF) was last updated on 12/11/2023 by MarketBeat.com Staff

My Account -